Biological Safety Cabinet Market Size by Type (Class I, Class II (Type A, Type B), Class III), End User (Pharmaceutical & Biopharmaceutical Companies, Diagnostic & Testing Laboratories, Academic Research Institutes), and Region - Global Forecast to 2027
The global size of biological safety cabinet market in terms of revenue was estimated to be worth USD 0.2 billion in 2022 and is poised to reach USD 0.4 billion by 2027, growing at a CAGR of 8.2% from 2022 to 2027. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
Market growth is driven by the increased research in pharmaceutical industry and rapid growth in vaccine development for communicable diseases.
e-estimated, p-projected
To know about the assumptions considered for the study, Request for Free Sample Report
Biological Safety Cabinet Market Dynamics
Driver: Favorable regulations
Increased government regulations on healthcare industries specifically focused on safety are increased significantly. Due to the increased demand of high quality healthcare products pharmaceutical and biopharmaceutical companies have increased the use of biological safety cabinets. These regulatory requirements for the use of biological safety cabinets will drive the mrket growth.
Opportunity: Emerging market offers lucrative growth opportunities
There is an increase in funding and increased R&D expenditure offered by government and private institutions is expected to offer significant growth opportunities. The pharmaceutical industry in the emerging market invest heavily in drug development, the growing demand for new drug molecules offer great opportunity for biological safety cabinets.
Restraint: Alternative containment cabinets
There is significant increase in the development of efficient and reliable alternatives of the biosafety cabinets. These devices provide better sterility as compared to biosafety cabinets and are majorly used in pharmaceutical and biopharmaceutical companies.
Class II segment accounted for the largest share of the biological safety cabinet industry, by type
The biological safety cabinet market is segmented into class I, class II and class III. The class II segment accounted for the largest share of the biological safety cabinet market, mainly due to the rising investment for development of new drug molecules.
Pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the biological safety cabinet industry, by end user
The biological safety cabinet market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and testing laboratories and academic research institutes based on end user. Pharmaceutical and biopharmaceutical companies segment accounted for the largest share. Factors such as increased need of biologics leads to market growth.
North America is the largest regional market for biological safety cabinet industry
The global biological safety cabinet market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the global biological safety cabinet market. The North American biological safety cabinet market's growth can be attributed to the increase in communicable diseases.
To know about the assumptions considered for the study, download the pdf brochure
Global leading companies operating in the global Biological Safety Cabinet Market are:
- Thermo Fisher Scientific (US)
- Kewaunee Scientific (US)
- Labconco (US)
- Esco Micro (Singapore)
- The Baker Company (US)
- NuAire (US)
- Germfree Laboratories (US)
- Cruma (Spain)
- Air Science (US)
- Berner International (US)
- Azbil telstar (Spain)
- LaboGene (Denmark)
- Biolab Scientific (Canada)
- Lamsystems (Germany)
- Faster S.R.L (Italy)
Scope of the Biological Safety Cabinet Industry
|
Report Metrics |
Details |
|
Market Revenue in 2022 |
$0.2 billion |
|
Projected Revenue by 2027 |
$0.4 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 8.2% |
|
Market Driver |
Increased favorable government regulations on healthcare industries |
|
Market Opportunity |
Emerging market offers lucrative growth opportunities |
This report categorizes the global biological safety cabinet market to forecast revenue and analyze trends in each of the following submarkets:
By Type
- Class I
- Class II
- Class III
By End User
- Pharmaceutical and Biopharmaceutical Companies
- Diagnostic and Testing Laboratories
- Academic Research Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments of Biological Safety Cabinet Industry
- In May 2021, Labconco (US) launched newly updated axiom biosafety cabinets.
- In December 2020, Labconco (US) unveiled a 65% larger class II enclosure uniquely designed for lab instrumentation.
- In May 2019, Labconco (US) unveiled updated logic+ biosafety cabinets with exclusive features for safety, ergonomics, and an updated operating system.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global biological safety cabinet market?
The global biological safety cabinet market boasts a total revenue value of $0.4 billion by 2027.
What is the estimated growth rate (CAGR) of the global biological safety cabinet market?
The global biological safety cabinet market has an estimated compound annual growth rate (CAGR) of 8.2% and a revenue size in the region of $0.2 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 22)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 BIOLOGICAL SAFETY CABINET INDUSTRY SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 26)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 BIOLOGICAL SAFETY CABINET INDUSTRY: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 37)
FIGURE 8 BIOLOGICAL SAFETY CABINETINDUSTRY, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 40)
4.1 MARKET OVERVIEW
FIGURE 11 INCREASED RISK OF PANDEMICS AND COMMUNICABLE DISEASES TO DRIVE MARKET
4.2 MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 12 CLASS II SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 13 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES—LARGEST END USERS OF BIOLOGICAL SAFETY CABINETS
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH IN FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 BIOLOGICAL SAFETY CABINET INDUSTRY: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Favorable regulations
5.2.1.2 Increased risk of pandemics and communicable diseases
5.2.1.3 Increasing number of R&D activities in pharmaceutical and biopharmaceutical companies
FIGURE 16 R&D SPENDING BY PHRMA MEMBER COMPANIES, 2001–2019 (USD BILLION)
TABLE 1 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2019 VS. 2026 (USD BILLION)
5.2.1.4 Rapid growth in biologics
FIGURE 17 TOTAL NUMBER OF NEW BIOLOGICS LICENSE APPLICATION APPROVALS, NDA APPROVALS, AND FILINGS (2005–2019)
TABLE 2 US: LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS, 2019
5.2.1.5 Growing concerns over cell culture contamination
5.2.2 RESTRAINTS
5.2.2.1 Alternative containment cabinets
5.2.2.2 High cost of biological safety cabinets
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets offer lucrative growth opportunities
5.3 PRICING ANALYSIS
TABLE 3 PRICE OF BIOLOGICAL SAFETY CABINETS (2021)
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS OF MARKET
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET MAP
FIGURE 21 MARKET: ECOSYSTEM/MARKET MAP
TABLE 4 MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 BIOLOGICAL SAFETY CABINET INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY LANDSCAPE
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR LABORATORY MACHINERY AND EQUIPMENT
TABLE 11 IMPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 12 EXPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 13 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
FIGURE 22 REVENUE SHIFT IN MARKET
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINETS (%)
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
TABLE 15 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS
5.15 CASE STUDIES
5.15.1 CASE STUDY: LABORATORY BIOLOGICAL SAFETY CABINET (BSC) EXPLOSION
6 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE (Page No. - 66)
6.1 INTRODUCTION
TABLE 16 BIOLOGICAL SAFETY CABINET INDUSTRY, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 MARKET, BY TYPE, 2020–2027 (THOUSAND UNITS)
6.2 CLASS I
6.2.1 GOVERNMENT INITIATIVES TO DRIVE MARKET
TABLE 18 CLASS I MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 CLASS II
TABLE 19 CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 20 CLASS II MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 CLASS II TYPE A
6.3.1.1 Increased usage of Class II Type A biosafety cabinets in laboratories to support market growth
TABLE 21 CLASS II TYPE A MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 CLASS II TYPE B
6.3.2.1 Class II Type B cabinets used for volatile and toxic chemicals
TABLE 22 CLASS II TYPE B MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 CLASS III
6.4.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 23 CLASS III MARKET, BY REGION, 2020–2027 (USD MILLION)
7 BIOLOGICAL SAFETY CABINET MARKET, BY END USER (Page No. - 73)
7.1 INTRODUCTION
TABLE 24 BIOLOGICAL SAFETY CABINET INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
7.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
7.2.1 INCREASING R&D EXPENDITURE ENABLES COMPANIES TO INVEST IN HIGH-END BIOSAFETY CABINETS
TABLE 25 MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
7.3 DIAGNOSTIC AND TESTING LABORATORIES
7.3.1 RISING PREVALENCE OF DISEASES TO SUPPORT MARKET GROWTH
TABLE 26 MARKET FOR DIAGNOSTIC AND TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
7.4 ACADEMIC RESEARCH INSTITUTES
7.4.1 INCREASING NUMBER OF RESEARCH ACTIVITIES AND RISING GOVERNMENT FUNDING FOR MEDICAL RESEARCH TO SUPPORT MARKET GROWTH
TABLE 27 MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
8 BIOLOGICAL SAFETY CABINET MARKET, BY REGION (Page No. - 78)
8.1 INTRODUCTION
TABLE 28 BIOLOGICAL SAFETY CABINET INDUSTRY, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MARKET SNAPSHOT
TABLE 29 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Growth in biosimilars market to boost preclinical research
TABLE 33 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 34 US: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 35 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Government support for R&D to support market growth
TABLE 36 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 CANADA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 39 EUROPE: BIOLOGICAL SAFETY CABINET INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 EUROPE: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 42 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Increased funding and growth of research sector to drive market
TABLE 43 GERMANY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 GERMANY: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Increasing awareness about safety in high-risk environments to propel market
TABLE 46 UK: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 UK: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing healthcare industry to provide growth opportunities
TABLE 49 FRANCE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 FRANCE: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.4 REST OF EUROPE
TABLE 52 REST OF EUROPE: BIOLOGICAL SAFETY CABINET INDUSTRY, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 REST OF EUROPE: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 55 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Largest market for biological safety cabinets in Asia Pacific
TABLE 59 JAPAN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 JAPAN: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Government initiatives in drug development to support market growth
TABLE 62 CHINA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 CHINA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Growing pharmaceutical industry to drive market
TABLE 65 INDIA: BIOLOGICAL SAFETY CABINET INDUSTRY, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 INDIA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 68 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 REST OF ASIA PACIFIC: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 FAVORABLE GOVERNMENT POLICIES AND INCREASING DEMAND FOR NEW DRUG MOLECULES—KEY FACTORS DRIVING MARKET
TABLE 71 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 LATIN AMERICA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST AND AFRICA
8.6.1 INCREASING R&D INVESTMENTS AND FOCUS ON DEVELOPMENT OF NEW DRUGS TO DRIVE MARKET
TABLE 74 MIDDLE EAST AND AFRICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA: CLASS II MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 108)
9.1 OVERVIEW
9.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOLOGICAL SAFETY CABINET INDUSTRY
TABLE 77 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOLOGICAL SAFETY CABINET MANUFACTURING COMPANIES
9.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MARKET
9.4 MARKET SHARE ANALYSIS
FIGURE 28 MARKET SHARE, BY KEY PLAYER (2021)
TABLE 78 MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT
9.5.1 LIST OF EVALUATED VENDORS
9.5.2 STARS
9.5.3 EMERGING LEADERS
9.5.4 PERVASIVE PLAYERS
9.5.5 PARTICIPANTS
FIGURE 29 BIOLOGICAL SAFETY CABINET INDUSTRY: COMPETITIVE LEADERSHIP MAPPING, 2021
9.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
FIGURE 30 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
9.7 COMPETITIVE BENCHMARKING
9.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN MARKET
TABLE 79 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 80 PRODUCT FOOTPRINT OF COMPANIES
TABLE 81 REGIONAL FOOTPRINT OF COMPANIES
TABLE 82 BIOLOGICAL SAFETY CABINET INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
9.8 COMPETITIVE SCENARIO
9.8.1 PRODUCT LAUNCHES
TABLE 83 KEY PRODUCT LAUNCHES
10 COMPANY PROFILES (Page No. - 118)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 THERMO FISHER SCIENTIFIC
TABLE 84 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.2 KEWAUNEE SCIENTIFIC
TABLE 85 KEWAUNEE SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 33 KEWAUNEE SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.3 LABCONCO
TABLE 86 LABCONCO: BUSINESS OVERVIEW
10.1.4 ESCO MICRO
TABLE 87 ESCO MICRO: BUSINESS OVERVIEW
10.1.5 THE BAKER COMPANY
TABLE 88 THE BAKER COMPANY: BUSINESS OVERVIEW
10.1.6 NUAIRE
TABLE 89 NUAIRE: BUSINESS OVERVIEW
10.1.7 GERMFREE LABORATORIES
TABLE 90 GERMFREE LABORATORIES: BUSINESS OVERVIEW
10.1.8 CRUMA
TABLE 91 CRUMA: BUSINESS OVERVIEW
10.1.9 AIR SCIENCE
TABLE 92 AIR SCIENCE: BUSINESS OVERVIEW
10.1.10 BERNER INTERNATIONAL
TABLE 93 BERNER INTERNATIONAL: BUSINESS OVERVIEW
10.1.11 AZBIL TELSTAR
TABLE 94 AZBIL TELSTAR: BUSINESS OVERVIEW
10.1.12 LABOGENE
TABLE 95 LABOGENE: BUSINESS OVERVIEW
10.1.13 BIOLAB SCIENTIFIC
TABLE 96 BIOLAB SCIENTIFIC: BUSINESS OVERVIEW
10.1.14 LAMSYSTEMS GMBH
TABLE 97 LAMSYSTEMS GMBH: BUSINESS OVERVIEW
10.1.15 FASTER S.R.L.
TABLE 98 FASTER S.R.L.: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 MRC LABORATORY EQUIPMENT
TABLE 99 MRC LABORATORY EQUIPMENT: COMPANY OVERVIEW
10.2.2 NANBEI INSTRUMENT LIMITED
TABLE 100 NANBEI INSTRUMENT LIMITED: COMPANY OVERVIEW
10.2.3 THERMOLAB
TABLE 101 THERMOLAB: COMPANY OVERVIEW
10.2.4 LABMATE
TABLE 102 LABMATE: COMPANY OVERVIEW
10.2.5 TOPAIR SYSTEMS, INC.
TABLE 103 TOPAIR SYSTEMS, INC.: COMPANY OVERVIEW
10.2.6 ALBIAN GROUP
TABLE 104 ALBIAN GROUP: COMPANY OVERVIEW
10.2.7 THOMAS SCIENTIFIC
TABLE 105 THOMAS SCIENTIFIC: COMPANY OVERVIEW
10.2.8 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.
TABLE 106 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
10.2.9 STERICOX
TABLE 107 STERICOX: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 154)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the biological safety cabinet market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the biological safety cabinet market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the biological safety cabinet market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Biological Safety Cabinet Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the biological safety cabinet market by type, end user and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints and opportunities).
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa,
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2.
- To track and analyze company developments such as product launches in the biological safety cabinet market.
- To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Biological safety cabinet market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa.
Company profiles
- Product portfolio matrix for leading market players.
Generating Response ...
Growth opportunities and latent adjacency in Biological Safety Cabinet Market